ObsEva (ObsEva) Scaled Net Operating Assets : 0.18 (As of Dec. 2022)

View and export this data going back to 2017. Start your Free Trial

What is ObsEva Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

ObsEva's operating assets for the quarter that ended in Dec. 2022 was $8.12 Mil. ObsEva's operating liabilities for the quarter that ended in Dec. 2022 was $5.03 Mil. ObsEva's Total Assets for the quarter that ended in Sep. 2022 was $16.81 Mil. Therefore, ObsEva's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2022 was 0.18.

ObsEva Scaled Net Operating Assets Historical Data

The historical data trend for ObsEva's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ObsEva Scaled Net Operating Assets Chart

ObsEva Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.06

0.04

-0.42

0.05

ObsEva Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Scaled Net Operating Assets	Get a 7-Day Free Trial															-0.28	0.07	0.19	-0.07	0.18

Competitive Comparison of ObsEva's Scaled Net Operating Assets

For the Biotechnology subindustry, ObsEva's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ObsEva's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ObsEva's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where ObsEva's Scaled Net Operating Assets falls into.

ObsEva Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

ObsEva's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2022 )
=	(Operating Assets (A: Dec. 2022 )	-	Operating Liabilities (A: Dec. 2022 ))	/	Total Assets (A: Dec. 2021 )
=	(8.12	-	5.034)	/	64.536
=	0.05

where

	Operating Assets		(A: Dec. 2022 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	16.544	-	8.424
=	8.12

	Operating Liabilities		(A: Dec. 2022 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	8.061	-	0	-	3.027
=	5.034

ObsEva's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2022 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2022 )
=	(Operating Assets (Q: Dec. 2022 )	-	Operating Liabilities (Q: Dec. 2022 ))	/	Total Assets (Q: Sep. 2022 )
=	(8.12	-	5.034)	/	16.807
=	0.18

where

	Operating Assets		(Q: Dec. 2022 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	16.544	-	8.424
=	8.12

	Operating Liabilities		(Q: Dec. 2022 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	8.061	-	0	-	3.027
=	5.034

ObsEva Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of ObsEva's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

ObsEva (ObsEva) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (GREY:OBSEF) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228

Website

https://www.obseva.com

ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.

Executives

William Michael Brown	officer: Chief Financial Officer	910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Anne Vanlent	director	C/O BARRIER THERAPEUTICS, INC., 600 COLLEGE ROAD EAST, SUITE 3200, PRINCETON NJ 08540
Edward T Mathers	director	C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Brian O'callaghan	director, officer: Chief Executive Officer	550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Ernest Loumaye	director	C/O OBSEVA SA, CHEMIN DES AULX, 12, OLAN-LES-OUATES, GENEVA V8 1228
Catarina Edfjall	director	C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 0000000000
Annette Clancy	director	C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 1228
Stephanie Clare Brown	director	C/O OBSEVA SA, CHEMIN DES AULX, 12, 1228 PLAN-LES-OUATE, GENEVA V8 1228